Titan Pharmaceuticals, Inc.
News
Titan Pharmaceuticals (NASDAQ:TTNP) Research Coverage Started at StockNews.com
Ticker Report Analysts at StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP - Get Free Report) in a research report issued on Friday. The brokerage set a "sell" rating on the specialty...\n more…
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Titan Pharmaceuticals, Inc. TTNP
Globe Newswire NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the M&A Class Action Firm ), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS...\n more…
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Titan Pharmaceuticals, Inc. - TTNP
PR Newswire SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Titan Pharmaceuticals, Inc. - TTNP SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Titan...\n more…
Titan Pharmaceuticals (NASDAQ:TTNP) Coverage Initiated by Analysts at StockNews.com
Ticker Report StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP - Free Report) in a research report report published on Thursday. The brokerage issued a sell rating on the specialty...\n more…
Titan Pharmaceuticals (NASDAQ:TTNP) Stock Price Crosses Below 200-Day Moving Average of $6.64
Ticker Report Titan Pharmaceuticals, Inc. (NASDAQ:TTNP - Get Free Report) shares crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $6.64 and traded as...\n more…
Shareholder Alert: Ademi LLP investigates whether Titan Pharmaceuticals, Inc. has obtained a Fair Price for its Public Shareholders
PR Newswire Shareholder Alert: Ademi LLP investigates whether Titan Pharmaceuticals, Inc. has obtained a Fair Price for its Public Shareholders Shareholder Alert: Ademi LLP investigates whether Titan...\n more…